ALSO NOTED: Alexza gains $50M; AstraZeneca, Cubist sign $10.25M licensing pact; and much more...

> Symphony Capital Partners will provide $50 million to Alexza Pharmaceuticals for the development of AZ-002 and AZ-004, both of which are in Phase II trials. Release

> Shanghai-based Cathay Industrial Biotech has closed a $52 million second round of financing. Investors include Goldman Sachs, Gramineae Holdings Company Limited, GM Investment Company Limited and New Horizon Evergreen Investment. Report

> Procter & Gamble Pharmaceuticals has announced that a trial of Asacol delayed-release tablets in patients with ulcerative colitis demonstrated a statistically significant improvement in overall quality of life. Report

> AstraZeneca has entered into a $10.25M licensing pact with Cubist Pharmaceuticals to develop and commercialize the antibiotic Cubicin in China and other Asian, Middle East and African countries. The deal does not included commercialization in Japan. Report

And Finally... 'Super' enzyme may lead the way to better tumor vaccines. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.